Uncategorized
Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study
Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study
The Phase 2 study was small and was not designed to establish the statistical difference between Vistagen’s drug candidate and placebo, according to Vistagen. The biotech plans to meet with the FDA to determine a registrational path for the asset. Read More